Recent Updates
Recently added Catalysts
NMTC

NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock

Key Takeaway: NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock PRAIRIE, MN., October 12, 2021 - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the "Company"), a medical technology company focused on improving surgical care options and o

Full Press Release Details

NeuroOne Medical Technologies
Corporation Announces Proposed Public Offering of Common Stock
PRAIRIE, MN., October 12, 2021 - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the "Company"), a medical technology
company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced
that it has commenced a proposed underwritten registered public offering of shares of its common stock.
All of the shares of common stock to be sold
in the proposed offering will be sold by the Company. In addition, the Company intends to
grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the offering. The
proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed,
or as to the actual size or terms of the offering.
Company intends to use the net proceeds from this proposed offering for working capital and other general corporate purposes.
Craig-Hallum Capital Group is acting as the
sole managing underwriter for the proposed offering.
The proposed offering is being made pursuant
to a shelf registration statement on Form S-3 (File No. 333-256830) that was declared effective by the U.S. Securities and Exchange Commission
("SEC"), on June 14, 2021. A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering
will be filed with the SEC and will be available on the SEC's website at www.sec.gov or by contacting Craig-Hallum Capital Group
LLC, 222 South Ninth Street, Suite 350, Minneapolis, MN 55402, Attn: Equity Capital Markets, telephone: 612-334-6300 or by email at prospectus@chlm.com.
This press release does not and shall not
constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in
any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of a prospectus, including
a prospectus supplement, forming a part of the effective registration statement.
NeuroOne Medical Technologies Corporation
is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation
and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed
back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information,
Forward Looking Statements
This press release may include forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward-looking
statement that reflects the Company's current views about future events and are subject to known and unknown risks, uncertainties and
other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information
expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the words
"may," "might," "will," "could," "would," "should," "expect," "intend,"
"plan," "objective," "anticipate," "believe," "estimate," "predict," "project,"
"potential," "target," "seek," "contemplate," "continue" and "ongoing," or
the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements
include statements related to the proposed offering and expected use of proceeds. Although the Company believes that we have a reasonable
basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently
known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different
from what we expect due to factors largely outside our control, including risks and uncertainties related to market and other conditions,
the satisfaction of customary closing conditions related to the proposed public offering, the impact of general economic, industry or
political conditions in the United States or internationally and those described under the heading "Risk Factors" in our filings
with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release and
the Company undertakes no obligation to revise or update any forward-looking statements for any reason, even if new information
becomes available in the future.
Last updated: Oct 12, 2021